Table 1.
Main characteristics of the included studies
| Study | Year | Tumor type | No. of Patients | Male/Female | median age (range) (year) | Staining | TATE: Present / absent | Tumor stage | median follow-up date (months) | Survival | Quality Score (NOS) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Peurala, E. etal [15] | 2018 | Oral cancer | 99 | 55/44 | 65.3 | H&E | 51/47 | I - III | 40.7 | OS | 8 |
| Oliveira, D. T. etal [16] | 2012 | Oral cancer | 71 | 55/16 | 59 (35, 77) | H&E | 35/36 | I - II | NR | DFS | 7 |
| Tostes Oliveira, D. etal [19] | 2009 | Oral cancer | 43 | 27/16 | 55.79 (28, 83) | H&E | 21/22 | I - IV | (3, 229) | OS | 7 |
| Dorta, R. G. etal [17] | 2002 | Oral cancer | 125 | 105/20 | 58 (30, 95) | H&E | 57/68 | II - III | 88.2 (0, 287.4) | OS, DFS | 7 |
| Dante, P. etal [40] | 2019 | Tongue Carcinoma | 259 | 223/36 | 53.0 ± 12.2 | H&E | NR | I - IV | NR | OS, DFS | 8 |
| Alrawi, S. J. etal [18] | 2005 | Head and neck carcinoma | 87 | NR | (41, 76) | H&E | 13/7 | II - IV | 36 (6, 216) | OS, DFS | 7 |
| Ercan, I. etal [20] | 2005 | Laryngeal carcinoma | 78 | 78/0 | 55.9 (35, 80) | H&E | 25/53 | NR | 41.91 | OS | 7 |
| Sassler, A. M. etal [21] | 1995 | Laryngeal carcinoma | 248 | NR | NR | H&E | 56/192 | III - IV | 48 | OS, DFS | 6 |
| Thompson, A. C. etal [22] | 1994 | Laryngeal carcinoma | 104 | 85/19 | 64.6 (39, 91) | H&E | 31/73 | NR | ≥ 60 | OS | 6 |
| Fujii, M. etal [23] | 2002 | Nasopharyngeal carcinoma | 53 | 40/13 | 49.4 (15, 81) | H&E | 26/27 | I - IV | 90.5 (35.3, 199.9) | DFS | 7 |
| Leighton, S. E. etal [24] | 1996 | Nasopharyngeal carcinoma | 96 | 68/28 | NR | H&E | 65/31 | NR | 57 | OS, DFS | 6 |
| Harbaum, L. etal [25] | 2015 | Colorectal cancer | 381 | 166/215 | 68.5 | H&E | 101/280 | I - IV | 45 (1, 182) | OS | 8 |
| Fernandez-Acenero, M. J. etal [26] | 2000 | Colorectal cancer | 126 | 70/56 | 67.35 (32, 87) | H&E | 29/97 | Duke’s A-C | ≥ 60 | OS, DFS | 8 |
| Nielsen, H.J. etal [27] | 1999 | Colorectal cancer | 584 | 240/344 | 61 (49, 75) | H&E | 150/115 | Duke’s A-D | 61 (49, 75) | OS | 7 |
| Prizment, A. E etal [28] | 2016 | Colorectal cancer | 441 | 0/441 | (55, 69) | H&E; EPX | 197 /244 | NR | 60 | OS | 8 |
| Zhang, Y. etal [29] | 2014 | Esophageal carcinoma | 36 | 25/11 | 59 (45, 77) | H&E | 18/18 | I - IV | 22 (2, 143) | OS | 7 |
| Ishibashi, S. etal [30] | 2006 | Esophageal carcinoma | 97 | 82/15 | 62.7 ± 8.9 | H&E | 30/31 | NR | 61.7 (5.3, 165.4) | OS | 7 |
| Hollander, P. etal [31] | 2018 | Hodgkin’s lymphoma | 459 | 242/217 | < 45: 68%; ≥45: 32% | H&E | NR | I - IV | 154.8 | OS | 8 |
| Kereszres, K. etal [32] | 2007 | Hodgkin’s lymphoma | 104 | 54/50 | 33 (12, 72) | H&E | 64/40 | I - IV | 110 (24, 214) | OS, DFS | 7 |
| von Wasielewski, R. etal [33] | 2000 | Hodgkin’s lymphoma | 1511 | 745/766 | (15, 75) | H&E | 510/823 | I - IV | 120 | OS | 8 |
| Enblad, G.etal [34] | 1993 | Hodgkin’s lymphoma | 140 | NR | 45 (11, 94) | H&E | 26/114 | I - IV | 48 (20, 85) | DFS | 6 |
| van Driel, W.J. etal [35] | 1996 | Cervical cancer | 83 | 0/83 | 42.1 | H&E | NR | I - IIA | 44.6 (5, 108) | OS, DFS | 7 |
| Bethwaite, P. B. etal [36] | 1993 | Cervical cancer | 67 | 0/67 | 43.7 (25, 76) | H&E | 28/39 | IB | 62.4 (1, 93) | OS | 7 |
| Flamm, J. etal [37] | 1992 | Bladder cancer | 428 | 289/139 | 70.2 (29, 91) | H&E | 99/329 | NR | 84 | OS | 7 |
| Iwasaki, K. etal [38] | 1986 | Gastric cancer | 647 | 364/283 | (22, 84) | H&E | 157/490 | I - IV | (8, 92) | OS | 7 |
| Ono, Y. etal [39] | 2002 | Penile cancer | 17 | 17/0 | 68 (36, 84) | H&E | 9/8 | I - IV | NR | OS | 6 |
H&E haematoxilyn and eosin, EPX eosinophil peroxide, NR not reported